AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
193.50
+1.43 (+0.74%)
As of 11:23AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close192.07
Open192.24
Bid193.26 x 1100
Ask193.25 x 900
Day's Range190.37 - 193.68
52 Week Range163.31 - 210.19
Volume670,661
Avg. Volume2,908,010
Market Cap123.302B
Beta (3Y Monthly)1.39
PE Ratio (TTM)60.32
EPS (TTM)3.21
Earnings DateJan 30, 2019 - Feb 4, 2019
Forward Dividend & Yield5.80 (3.02%)
Ex-Dividend Date2019-02-14
1y Target Est204.80
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

    THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab). "At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines.

  • Better Buy: Biogen vs. Amgen
    Motley Fool2 days ago

    Better Buy: Biogen vs. Amgen

    Which stock wins in a one-on-one matchup between these big biotechs?

  • PR Newswire3 days ago

    FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia

    THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.

  • 12 Stocks You Should Never Sell
    Kiplinger3 days ago

    12 Stocks You Should Never Sell

    Hopping in and out of stocks tends to do more harm than good to your portfolio. Fortunately, most of the time, investors are content to sit back and let time do the heavy lifting. Every now and then, however, an uninterrupted market-wide rally (such as the one we saw in 2017) followed by a couple of major corrections (such as the ones we've seen in 2018) inspires a more active approach. Buying every dip last year was a bulletproof strategy; steering clear of this year's big dips would've left most investors far better off. But broadly speaking, investors shouldn't embrace that short-term mindset. Buy-and-hold is a time-tested strategy that helps investors avoid trying to time the market (which even experts can't reliably do) and making poor emotional decisions. With that as a backdrop, here are a dozen stocks to never sell. Many buy-and-holders are looking to reset their portfolios as the new year begins. If you hold any of the stocks, don't stop ... and if you're looking to buy, be ready to commit. Each company has plenty to success that their history of success should continue for years to come. And each operates in an industry that won't go away anytime soon. SEE ALSO: 101 Best Dividend Stocks to Buy for 2019 and Beyond

  • Zacks3 days ago

    5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019

    The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.

  • Zacks3 days ago

    5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

    There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

  • PR Newswire4 days ago

    Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries

    THOUSAND OAKS, Calif. and SANTA BARBARA, Calif., Dec. 13, 2018 /PRNewswire/ -- Amgen (AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries access to Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim) and Vectibix® (panitumumab).

  • Amgen (AMGN) Gains But Lags Market: What You Should Know
    Zacks5 days ago

    Amgen (AMGN) Gains But Lags Market: What You Should Know

    In the latest trading session, Amgen (AMGN) closed at $196.41, marking a +0.12% move from the previous day.

  • Why Arrowhead Pharmaceuticals Surged 11% Higher Today
    Motley Fool5 days ago

    Why Arrowhead Pharmaceuticals Surged 11% Higher Today

    The company updated investors on its financial performance, and on its progress developing RNAi therapies.

  • Do Analysts See Any Upside for Regeneron Stock?
    Market Realist5 days ago

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.” Their mean rating for Regeneron stock is 2.58, and their target price is $426.05, implying a 12.8% upside for the stock based on its December 10 closing price of $377.59.

  • What Regeneron Pharmaceuticals’ Bottom Line Indicates
    Market Realist5 days ago

    What Regeneron Pharmaceuticals’ Bottom Line Indicates

    In this year’s third quarter, Regeneron Pharmaceuticals’ (REGN) interest expenses rose YoY (year-over-year) to $7.49 million from $6.18 million, and its net other income rose YoY to $16.43 million from $11.86 million. Its income tax expenses fell YoY to $41.21 million from $177.29 million.

  • Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 days ago

    Arrowhead Pharmaceuticals (ARWR) Q4 2018 Earnings Conference Call Transcript

    ARWR earnings call for the period ending September 30, 2018.

  • PR Newswire6 days ago

    Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions

    THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ -- Amgen (AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases. Based on Amgen and Magellan's extensive expertise in complex areas of health and specialty populations, the initial projects will focus on improving patient outcomes for the treatment of osteoporosis and migraine.

  • Understanding Seattle Genetics’ Operational Performance
    Market Realist6 days ago

    Understanding Seattle Genetics’ Operational Performance

    How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.

  • What Seattle Genetics’ Bottom-Line Trend Indicates
    Market Realist6 days ago

    What Seattle Genetics’ Bottom-Line Trend Indicates

    Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.

  • How’s Seattle Genetics Positioned?
    Market Realist6 days ago

    How’s Seattle Genetics Positioned?

    How's Seattle Genetics Positioned? Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

  • Understanding Regeneron Pharmaceuticals’ Operational Performance
    Market Realist6 days ago

    Understanding Regeneron Pharmaceuticals’ Operational Performance

    In the third quarter of this year, Regeneron Pharmaceuticals’ (REGN) selling, general, and administrative expenses rose YoY (year-over-year) to $369.23 million from $306.77 million, primarily due to a higher employee headcount. Meanwhile, its R&D (research and development) expenses rose YoY to $556.97 million from $529.75 million. It had R&D expenses of $2.03 billion and $2.23 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $2.07 billion in fiscal 2017.

  • Regeneron Pharmaceuticals’ Gross Margin Trends
    Market Realist6 days ago

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017. Meanwhile, peers Amgen (AMGN), Biogen (BIIB), and Johnson & Johnson (JNJ) are expected to have revenue of $23.36 billion, $13.31 billion, and $81.35 billion, respectively, in fiscal 2018. Regeneron’s cash per share is $20.14, while Amgen’s, Biogen’s, and Johnson & Johnson’s cash per share is $45.17, $21.31, and $7.20, respectively.

  • MarketWatch6 days ago

    Entera shares jump 11.5% on news of collaboration with Amgen

    Shares of Entera Bio Ltd. and Amgen Inc. rose Tuesday, after they announced a research collaboration in inflammatory disease and other serious illnesses. As part of the deal, Entera will use its proprietary drug delivery platform to develop oral versions of one preclinical large molecule program selected by Amgen. Amgen has the option of selecting two other programs to add to the collaboration. Entera will be eligible to receive up to $270 million in aggregate payments, along with tiered royalties up to mid-single digits upon reaching various milestones. It will retain IP rights to its technology. Entera shares rose 11.5% in early trade and are up 23% in the last three months, while the S&P 500 has fallen 7.7%. Amgen shares were up about 1%.

  • See what the IHS Markit Score report has to say about Amgen Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGN

  • PR Newswire7 days ago

    Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

    THOUSAND OAKS, Calif. and SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Amgen (AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S. Through a corporate donation, Amgen has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is focused on improving patient enrollment, retention, minority participation and equitable access in oncology trials. IMPACT aspires to create a new standard in clinical trial outreach allowing all cancer patients, regardless of their ability to pay for travel and other expenses, to participate in clinical trials evaluating new cancer treatment options.

  • Zacks7 days ago

    Amgen (AMGN) Continues to Reward Shareholders, Ups Dividend

    Amgen (AMGN) hikes its quarterly dividend by 10%.

  • Amgen Increases Quarterly Dividend
    GuruFocus.com8 days ago

    Amgen Increases Quarterly Dividend

    Amgen Inc. (AMGN) has informed the market Friday after closing bell that the board of directors of the company has authorized the payment of a quarterly dividend for the first trimester of fiscal 2019. The company will pay shareholders a cash dividend of $1.45 per share, reflecting a 9.8% increase from the previous one. Warning! GuruFocus has detected 2 Warning Signs with AABA.

  • Is AbbVie Inc (ABBV) A Good Stock To Buy?
    Insider Monkey9 days ago

    Is AbbVie Inc (ABBV) A Good Stock To Buy?

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]